StemCell Therapy

Highlights

Events and Activities

NIBGE Email

Welcome to NIBGE

PAEC has clear mandates on the safe use of modern sciences with an aim to improve the socio economic growth of the country. NIBGE is one of the main biotechnology institutes of the four bioscience centers of PAEC and was formally inaugurated by the President of Pakistan in 1994. It is also an affiliate center of ICGEB. The institute is a focal point of modern biotechnology and provides a technology receiving unit to help the development of country through applications of modern biotechnology and genetic engineering. The research programs at NIBGE are mainly aimed at improving agriculture, health, environment and industry and are supported by national and international financial grants. The institute research facilities include state of the art equipments supported by technical services, IT facility and a National Library for Biological Sciences. The institute now offers several services and marketable products. The educational programs leading to MPhil and PhD degrees have also been incorporated in the institutes mandate for the development of human resources in modern sciences.

Announcement

Interview Schedule of M.Phil (Biotechnology)

Featured News

Read more here:
Home :: National Institute for Biotechnology and Genetic ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT Trial) at the 2021 Society for Neuro-Oncology Annual Meeting. The presentation, entitled Preliminary results of the neratinib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a phase II platform trial using Bayesian adaptive randomization, was presented as an oral presentation in the Abstract Session: Clinical Trials II Session. A copy of the presentation is available on the Puma Biotechnology website.

The INSIGhT trial is a multisite investigator-initiated Phase II screening adaptive platform trial where patients with newly diagnosed unmethylated glioblastoma who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. All patients receive radiation therapy and temozolomide and then patients are randomized to receive either adjuvant temozolomide or adjuvant treatment with an experimental agent (neratinib). At the initiation of INSIGhT, three experimental arms, each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms were allowed to drop because of low probability of treatment impact on overall survival. The primary endpoint of INSIGhT is overall survival (OS). Progression-free survival (PFS) analysis is used to influence randomization. For the neratinib arm of the trial, patients received 240 mg of neratinib daily as a single agent with mandatory loperamide prophylaxis.

For the neratinib arm of the trial, there were 149 patients in the intent-to-treat population, including 81 patients treated with neratinib and 68 patients in the control arm. For the intent-to-treat population, PFS was not significantly longer (HR 0.75; p=0.12, log rank test) with neratinib (median 6.0 months) versus the control arm (median 4.7 months) and there was no significant improvement in OS (HR 1.01; p=0.75) between neratinib (median 13.8 months) vs. the control arm (median 14.7 months). For patients with activation of the EGFR pathway, defined as patients with either EGFR amplification or mutation, PFS was significantly longer (HR 0.58; p=0.04, log rank test) with neratinib (median 6.3 months) vs. the control arm (median 4.6 months); however, there was no significant improvement in overall survival (HR 0.97; p= 0.94) between neratinib (median 14.4 months) vs. the control arm (median 15.3 months).

Neratinib was generally well tolerated in the trial and toxicities for neratinib were similar to that previously described. For the 81 patients treated with neratinib, there were 6 cases (7.4%) of grade 3 diarrhea and no cases of grade 4 diarrhea. No new toxicity signals were identified in the trial.

Isabel Arrillaga-Romany, MD, PhD, Director of Neuro-Oncology Clinical Trials at Mass General Cancer Center, an investigator on the trial who presented the data at SNO, said, Although preliminary results did not achieve the primary endpoint, subgroup analyses demonstrated improved PFS in patients with EGFR activation and a non-significant trend toward improved overall survival in patients with EGFRVIII mutations, which could warrant further investigation. Additionally, we are very pleased that this trial reinforced feasibility of randomized Bayesian adaptive platform trials for newly diagnosed glioblastoma.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, We would like to thank the INSIGHT trial investigators and the patients for their participation in the trial. This is the first data demonstrating an effect of neratinib in EGFR amplified or mutated glioblastoma. While we are not looking to pursue further clinical investigations of neratinib in this indication, we are evaluating the potential to develop a backup compound HKI-357, which has preclinically demonstrated better EGFR activity, in this indication.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Pumas business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Originally posted here:
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting - Business Wire

BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart, who joins the team as Chief Business Officer (CBO).

Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University.

We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts, said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.

About GRO Biosciences

GRO Biosciences (GRObio) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Companys NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005427/en/

Read more from the original source:
GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer - BioSpace

Polymerase Chain Reaction (PCR) Sales to Surpass US$ 12 Bn through 2031 as Adoption of Real-Time PCR Surges amid COVID-19

Fact.MRs latest study discusses factors affecting the polymerase chain reaction (PCR) market growth. It provides in-depth analysis of various market segments, including product and end user across seven major regions. The report further profiles leading PCR manufacturers and examines the effect of their growth strategies on the global market.

Fact.MR A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global polymerase chain reaction (PCR) market will reach US$ 3.6 Bn by the end of 2021. Owing to the surging demand for PCR products, the overall market is projected to register growth at 10% CAGR between 2021 and 2031.

Sales in the PCR market are expected to increase with rising prevalence of target diseases and genetic disorders. Also, factors such as growing popularity of portable PCR testing kits, advancements in PCR technology, and increasing government funding for research activities will facilitate the growth in the market.

PCR has emerged as an ideal technique for the amplification of DNA sequences. It is a simple and cost-effective technique which produces results rapidly. It is an extensively used technique in medical laboratory research for a wide range of applications including biomedical research and criminal forensics.

The unprecedented outbreak of COVID-19 had a positive impact on the PCR market. It created huge demand for reliable and rapid detection techniques such as RT-PCR. Various companies also launched novel PCR test kits for the detection of virus.

Also, RT-PCR emerged as an ideal technique for detection of COVID-19 virus. It is significantly faster and has lower risk of contamination or errors.

Request a report sample to gain compressive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4861

As per Fact.MR analysis, PCR reagents will account for around 60% of total PCR market revenue by 2031. Rising demand for diagnostic tests and launch of new reagents specific to the test type are some key factors accelerating the demand for reagents used in polymerase chain reaction. Furthermore, RT PCR systems market to witness significant growth.

Regionally, North America will continue to dominate the PCR market, owing to the presence of a well-established healthcare infrastructure, continuous advances in clinical research, and high prevalence of genetic disorders such as Klinefelter's syndrome and Down syndrome. The region is poised to expand at a healthy growth rate of 7.5% annually.

However, Asia is projected to register the fastest growth on the back of increasing penetration of PCR products, rising government support, high prevalence of chronic diseases, and expanding healthcare infrastructure.

As the demand for PCR continues to rise, leading manufacturers are moving towards developing portable micro-scale devices. They also are introducing advanced PCR instruments, reagents and consumable that will allow quick nucleic acid amplification. This is expected to create growth opportunities for the market, says a Fact.MR analyst

Key Takeaways from Polymerase Chain Reaction Market Survey

Key Drivers

Key Restraints

To gain in-depth insights on Polymerase Chain Reaction Market, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4861

Competitive Landscape

Key players operating in the polymerase chain reaction market are embracing advanced technologies for the development of new products. They have adopted various strategies such as mergers, partnerships, collaborations and manufacturing of advanced portable PCR products to increase their sales.

Some of the prominent players operating in the polymerase chain reaction market profiled by Fact.MR are:

More Insights on the Global Polymerase Chain Reaction Sales Outlook

Fact.MR provides an incisive coverage on global polymerase chain reaction market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for polymerase chain reaction with a detailed segmentation on the basis of:

Key Questions Covered in the Polymerase Chain Reaction Market Outlook Report

Explore Fact.MRs Coverage on the Healthcare Domain

Rapid Medical Diagnostic Kits Market- Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth. Blood glucose testing is in high demand, and it has been growing at the quickest rate of all types of tests across all geographies. Technology advancements and strategic alliances by key market players have paved the way for rapid medical diagnostic kit innovations.

COVID-19 Saliva-based Detection Kits- COVID-19 detection treatments are likely to be in high demand due to the availability of COVID-19 virus variants and the continued danger of infection. Manufacturers are focusing on delivering cost-effective and convenient testing solutions as COVID-19 diagnostics become more widely employed. While vaccination initiatives have reduced the incidence rate in some nations, the virus continues to represent a serious concern and has a high occurrence rate due to mutant forms. Future viral mutant strains, as well as increased knowledge of COVID-19 testing, are predicted to maintain market growth.

PCR and Real-time PCR Molecular Diagnostics Market - The COVID-19 pandemic has boosted prospects for the growth of the PCR and real-time PCR molecular diagnostics market. Real-time (qPCR) and digital (dPCR) PCR tests have been used in a variety of healthcare settings to detect and diagnose potential cases. Because of its high sensitivity, healthcare providers have embraced PCR tests on a large scale. As a result of such trends, the global PCR and real-time PCR molecular diagnostics market is poised to soar to new heights, surpassing a significant revenue threshold in the coming decade.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.

MarketNgage is powered by Fact.MR our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgagesMarket Research Subscriptionwith FREE credits. MarketNgage is powered by Fact.MR A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Continue reading here:
Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows - BioSpace

Northampton, MA --News Direct-- Illumina

Were honored to be named to the prestigious 2021 Dow Jones Sustainability Indices for a third year in a row. Illumina received the highest score in the Pharmaceuticals, Biotechnology and Life Sciences industry.

Inclusion in the DJSI highlights our commitment to continuously improving and growing our Corporate Social Responsibility (CSR) program to build a more sustainable and equitable future for all. Our program focuses on accelerating access to genomics, supporting our communities, and integrating environmental stewardship into our operations.

If you would like to hear more about our CSR program, join us at our inaugural ESG Investor event on Tuesday Nov 16 at 11 am PT.

Thank you to all our employees for championing the needs of patients, customers, our communities, and our planet.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/illumina-named-to-2021-dow-jones-sustainability-indices-with-highest-score-in-pharmaceuticals-biotechnology-and-life-sciences-industry-107725996

Excerpt from:
Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry - Yahoo...

The report on Global Food Biotechnology Market has been provided by researchers for a detailed understanding of market performance over an estimated period of time set from 2021 to 2026. However, this report has introduced a brief overview to provide the reader with better information on this report. This brief description contains a basic definition of the product or service studied in the report. Along with this, it also contains a summary of the main applications of this product or service in various industrial sectors. In addition, market research experts have also provided information on the manufacture or production of the product or service and its distribution strategy.

Other important factors studied in the global Food Biotechnology market report include demand and supply dynamics, industrial processes, import and export scenarios, R&D development activities and cost structures. In addition, this report also calculates figures for demand and supply for consumption, production cost, gross profit margins and sales price for products.

Get FREE Sample copy of this Report with Graphs and Charts at:https://reportsglobe.com/download-sample/?rid=289972

The segmentation chapters enable readers to understand aspects of the market such as its products, available technology and applications. These chapters are written to describe their development over the years and the course they are likely to take in the coming years. The research report also provides detailed information on new trends that may define the development of these segments in the coming years.

Food Biotechnology Market Segmentation:

Food Biotechnology Market, By Application (2016-2027)

Food Biotechnology Market, By Product (2016-2027)

Major Players Operating in the Food Biotechnology Market:

Company Profiles This is a very important section of the report that contains accurate and detailed profiles for the major players in the global Food Biotechnology market. It provides information on the main business, markets, gross margin, revenue, price, production and other factors that define the market development of the players studied in the Food Biotechnology market report.

Global Food Biotechnology Market: Regional Segments

The different section on regional segmentation gives the regional aspects of the worldwide Food Biotechnology market. This chapter describes the regulatory structure that is likely to impact the complete market. It highlights the political landscape in the market and predicts its influence on the Food Biotechnology market globally.

Get up to 50% discount on this report at:https://reportsglobe.com/ask-for-discount/?rid=289972

The Study Objectives are:

This report includes the estimation of market size for value (million USD) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Food Biotechnology market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Some Major Points from Table of Contents:

Chapter 1. Research Methodology & Data Sources

Chapter 2. Executive Summary

Chapter 3. Food Biotechnology Market: Industry Analysis

Chapter 4. Food Biotechnology Market: Product Insights

Chapter 5. Food Biotechnology Market: Application Insights

Chapter 6. Food Biotechnology Market: Regional Insights

Chapter 7. Food Biotechnology Market: Competitive Landscape

Ask your queries regarding customization at: https://reportsglobe.com/need-customization/?rid=289972

How Reports Globe is different than other Market Research Providers:

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email: [emailprotected]

Website: Reportsglobe.com

Original post:
Food Biotechnology Market 2021 Detailed Analysis of top Ventures with Regional Outlook | Key Companies: ABS Global, Arcadia Biosciences, AquaBounty...

The market has been high on Cellect Biotechnology Ltd - ADR (APOP) stock recently. APOP gets a Bullish score from InvestorsObserver's Stock Sentiment Indicator.

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score.

As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend.

Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive.

InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend.

Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

Cellect Biotechnology Ltd - ADR (APOP) stock is trading at $4.17 as of 12:27 PM on Thursday, Feb 11, a decline of -$0.58, or -12.19% from the previous closing price of $4.75. The stock has traded between $3.92 and $4.70 so far today. Volume today is elevated. So far 667,963 shares have traded compared to average volume of 237,549 shares.

To see InvestorsObserver's Sentiment Score for Cellect Biotechnology Ltd - ADR click here.

Cellect Biotechnology Ltd is a biotechnology company that has developed a novel technology platform known as ApoGraft that functionally selects cells in order to improve the safety and efficacy of regenerative medicine and cell therapies. The company is developing its first product based on its ApoGraft technology platform, the ApoTainer kit that utilizes FasL- apoptotic protein.

Click Here to get the full Stock Score Report on Cellect Biotechnology Ltd - ADR (APOP) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more here:
Is Cellect Biotechnology Ltd - ADR (APOP) a Stock to Watch This Week? - InvestorsObserver

Lineage Cell Therapeutics Inc (LCTX) is near the top in its industry group according to InvestorsObserver. LCTX gets an overall rating of 81. That means it scores higher than 81 percent of stocks. Lineage Cell Therapeutics Inc gets a 95 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 81 would rank higher than 81 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Lineage Cell Therapeutics Inc (LCTX) stock is trading at $2.96 as of 3:02 PM on Friday, Feb 12, an increase of $0.13, or 4.59% from the previous closing price of $2.83. The stock has traded between $2.79 and $3.05 so far today. Volume today is 2,543,347 compared to average volume of 2,141,025.

Click Here to get the full Stock Score Report on Lineage Cell Therapeutics Inc (LCTX) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is Lineage Cell Therapeutics Inc (LCTX) The Right Choice in Biotechnology? - InvestorsObserver

Xeris Pharmaceuticals Inc (XERS) is near the top in its industry group according to InvestorsObserver. XERS gets an overall rating of 78. That means it scores higher than 78 percent of stocks. Xeris Pharmaceuticals Inc gets a 92 rank in the Biotechnology industry. Biotechnology is number 16 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 78 would rank higher than 78 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Xeris Pharmaceuticals Inc (XERS) stock has gained 7.47% while the S&P 500 has fallen 0% as of 10:19 AM on Friday, Feb 12. XERS is higher by $0.49 from the previous closing price of $6.63 on volume of 4,496,742 shares. Over the past year the S&P 500 is up 16.07% while XERS is higher by 72.64%. XERS lost -$3.10 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Xeris Pharmaceuticals Inc (XERS) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Continued here:
Is Xeris Pharmaceuticals Inc (XERS) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Artelo Biosciences Inc (ARTL) is around the top of the Biotechnology industry according to InvestorsObserver. ARTL received an overall rating of 73, which means that it scores higher than 73 percent of all stocks. Artelo Biosciences Inc also achieved a score of 89 in the Biotechnology industry, putting it above 89 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Artelo Biosciences Inc (ARTL) stock is trading at $3.06 as of 10:19 AM on Friday, Feb 12, a gain of $1.43, or 87.73% from the previous closing price of $1.63. The stock has traded between $2.62 and $3.67 so far today. Volume today is elevated. So far 111,532,303 shares have traded compared to average volume of 7,246,523 shares.

Click Here to get the full Stock Score Report on Artelo Biosciences Inc (ARTL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

More here:
Is Artelo Biosciences Inc (ARTL) the Top Pick in the Biotechnology Industry? - InvestorsObserver

In recent years, however, producers of grapefruit-flavored foods and drinks have not had it easy. Figures from the US Department of Agriculture tell the tale: In the winter of 199697, Florida farmers harvested 59 million boxes of grapefruit. This season, the forecast is for a mere 4.6 million boxes.

Worldwide, the production of grapefruit and other citrus is in peril because of the spread of the citrus greening disease, as well as temperature shifts and extreme weather caused by climate change. Meanwhile, demand for natural citrus flavoring has gone through the roof.

Marifaith Hackett, director of specialty chemicals for the consulting firm IHS Markit: When ingredients come out of by-products of something else, there is always the danger that supply and demand are really out of whack. If you are a purchasing manager, youre likely thinking, We just have to come up with something better.

In the flavor and fragrance industry, that something better may be a manufacturing platform based on fermentation using modified microbes.

Top flavor and fragrance companies have been quietly partnering with biotechnology firms for as long as 2 decades. Recently, their interest has become more public, thanks to acquisitions and in-house investments by firms such as BASF, Firmenich, Givaudan, and Takasago International. And biotech entrants, including Conagen and Manus Bio, are at work expanding the list of available molecules.

Click here to read the full article.

Photo source: Dreamstime.com

See original here:
Flavor and fragrance industries are embracing biotechnology - FreshPlaza.com

Autolus Therapeutics PLC (AUTL) is around the bottom of the Biotechnology industry according to InvestorsObserver. AUTL received an overall rating of 34, which means that it scores higher than 34 percent of all stocks. Autolus Therapeutics PLC also achieved a score of 23 in the Biotechnology industry, putting it above 23 percent of Biotechnology stocks. Biotechnology is ranked 16 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Autolus Therapeutics PLC (AUTL) stock is trading at $7.60 as of 11:19 AM on Friday, Feb 12, an increase of $0.46, or 6.5% from the previous closing price of $7.14. The stock has traded between $7.04 and $7.70 so far today. Volume today is high. So far 1,529,581 shares have traded compared to average volume of 657,454 shares.

Click Here to get the full Stock Score Report on Autolus Therapeutics PLC (AUTL) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

See the rest here:
Should You Buy Autolus Therapeutics PLC (AUTL) in Biotechnology Industry? - InvestorsObserver

The 48 rating InvestorsObserver gives to AgeX Therapeutics Inc (AGE) stock puts it near the middle of the Biotechnology industry. In addition to scoring higher than 46 percent of stocks in the Biotechnology industry, AGEs 48 overall rating means the stock scores better than 48 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

AgeX Therapeutics Inc (AGE) stock has risen 22.5% while the S&P 500 has fallen -0.2% as of 11:50 AM on Wednesday, Feb 10. AGE is higher by $0.54 from the previous closing price of $2.40 on volume of 416,032 shares. Over the past year the S&P 500 is up 16.26% while AGE is higher by 124.43%. AGE lost -$0.30 per share the over the last 12 months.

Click Here to get the full Stock Score Report on AgeX Therapeutics Inc (AGE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is AgeX Therapeutics Inc (AGE) the Top Pick in the Biotechnology Industry? - InvestorsObserver

A rating of 76 puts Summit Therapeutics Inc (SMMT) near the top of the Biotechnology industry according to InvestorsObserver. Summit Therapeutics Inc's score of 76 means it scores higher than 76% of stocks in the industry. Summit Therapeutics Inc also received an overall rating of 64, putting it above 64% of all stocks. Biotechnology is ranked 18 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Summit Therapeutics Inc (SMMT) stock is trading at $8.75 as of 2:56 PM on Wednesday, Feb 10, a decline of -$0.60, or -6.42% from the previous closing price of $9.35. The stock has traded between $8.50 and $10.41 so far today. Volume today is more active than usual. So far 440,384 shares have traded compared to average volume of 244,979 shares.

Click Here to get the full Stock Score Report on Summit Therapeutics Inc (SMMT) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more here:
Is Summit Therapeutics Inc (SMMT) The Right Choice in Biotechnology? - InvestorsObserver

AgeX Therapeutics Inc (AGE) is near the middle in its industry group according to InvestorsObserver. AGE gets an overall rating of 56. That means it scores higher than 56 percent of stocks. AgeX Therapeutics Inc gets a 59 rank in the Biotechnology industry. Biotechnology is number 18 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 56 means the stock is more attractive than 56 percent of stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

AgeX Therapeutics Inc (AGE) stock is trading at $2.46 as of 1:47 PM on Tuesday, Feb 9, a loss of -$0.22, or -8.21% from the previous closing price of $2.68. The stock has traded between $2.39 and $2.57 so far today. Volume today is more active than usual. So far 430,476 shares have traded compared to average volume of 299,401 shares.

Click Here to get the full Stock Score Report on AgeX Therapeutics Inc (AGE) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Link:
Is AgeX Therapeutics Inc (AGE) The Right Choice in Biotechnology? - InvestorsObserver

Bio-Path Holdings Inc (BPTH) is near the top in its industry group according to InvestorsObserver. BPTH gets an overall rating of 68. That means it scores higher than 68 percent of stocks. Bio-Path Holdings Inc gets a 83 rank in the Biotechnology industry. Biotechnology is number 15 out of 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Bio-Path Holdings Inc (BPTH) stock is trading at $8.90 as of 1:23 PM on Thursday, Feb 11, a loss of -$2.87, or -24.38% from the previous closing price of $11.77. The stock has traded between $8.60 and $11.48 so far today. Volume today is 2,787,467 compared to average volume of 3,445,362.

Click Here to get the full Stock Score Report on Bio-Path Holdings Inc (BPTH) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read more from the original source:
Is Bio-Path Holdings Inc (BPTH) a Winner in the Biotechnology Industry? - InvestorsObserver

The 66 rating InvestorsObserver gives to Celsion Corporation (CLSN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 78 percent of stocks in the Biotechnology industry, CLSNs 66 overall rating means the stock scores better than 66 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 66 means the stock is more attractive than 66 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Celsion Corporation (CLSN) stock is trading at $2.83 as of 9:58 AM on Thursday, Feb 11, an increase of $0.88, or 44.87% from the previous closing price of $1.95. The stock has traded between $2.56 and $3.48 so far today. Volume today is more active than usual. So far 42,653,017 shares have traded compared to average volume of 17,258,583 shares.

Click Here to get the full Stock Score Report on Celsion Corporation (CLSN) Stock.

Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.

You May Also Like

Read the original post:
Is Celsion Corporation (CLSN) a Winner in the Biotechnology Industry? - InvestorsObserver

The applications of biotechnology include therapeutics, diagnostics, and genetically modified crops for agriculture, processed food, bioremediation, waste treatment, and energy production.

Biotechnology is widely used in different fields such as medicine, agriculture, food processing, etc. to produce useful products for human benefits.

Global Application of Biotechnology Market is a new report published by Report Consultant in an effort to reveal not only the prominent but also the equally essential underlying aspects of this industry.

This Application of Biotechnology market report is available up to 40% discount for a limited time only@

https://www.reportconsultant.com/ask_for_discount.php?id=80571

Top Companies of Application of Biotechnology Market:

Gilead, Celgene, Abbott, Novo Nordisk A/S,Novartis AG, Sanofi Aventis, and Lonza

Reasons for buying this Application of Biotechnology market Report

The Application of Biotechnology Market report includes the statistics about the systematic approaches, which needs to follow for booming industries. It consists of different ways to analyze, seek, and shed light on new opportunities. This report consists of the estimated data about the drivers, restraints, and opportunities that can help to drive the flow of the businesses.

Try a sample of this Application of Biotechnology Market report now!@ https://www.reportconsultant.com/request_sample.php?id=80571

This report focuses on the important pillars of the businesses such as drivers, restraints and opportunities that either grow or obstruct the market. The Application of Biotechnology market research report includes an in-depth assessment of the global market. In addition to this, it covers the selling approaches of the industries to enlarge the businesses in the forthcoming years. It summarizes on the well-developed framework of the market to accomplish the risk factors obstacles that stand in front of the businesses. Report Consultant has concluded its statistical report by promoting the economic growth in the upcoming year 2021 to 2028.

About us:

Report Consultant is a prime destination for your business aptitude and analytical solutions because we provide qualitative and quantitative sources of information that are proficient to give one-stop solutions. We skillfully syndicate qualitative and quantitative research in exact proportions to have the best report, which not only gives the most recent insights but also assists you to grow.

Contact us:

Riaana Singh

(Report Consultant)

Contact No: +81-368444299

sales@reportconsultant.com

http://www.reportconsultant.com

See the article here:
Application of Biotechnology Market Emerging Trends and Prospects 2028 with Leading Vendors: Gilead, Celgene, Abbott, Novo Nordisk A/S,Novartis AG,...

With the support of the economic development organization Invest Puerto Rico, Biosimilar Solutions LLC announced that both it and CytoImmune Therapeutics will be establishing operations on the island to conduct biologics and cell therapy research and development.

According to the press release, CytoImmune will relocate to Toa Baja and plans to invest $28 million in the facility, which will be developing and marketing novel cancer immunotherapy products. CytoImmune currently develops proprietary Chimeric Antigen Receptor engineered t cells (CAR-T) technology, as well as an approach for human natural killer cell immunotherapy. Biosimilar Sciences will establish its new facility in Aguadilla, and plans $200 million of investment in machinery and equipment to develop a series of biosimilar products including a COVID-19 vaccine.

This announcement is a clear indication thatPuerto Ricosbusiness ecosystem is primed to support bioscience innovation, manufacturing, and distribution on a global scale. It also shows that this sector is crucial to the Islands path to economic transformation since biotechnology start-ups can provide hundreds of jobs upon a successful FDA approval. We proudly welcome CytoImmune and Biosimilar toPuerto Ricoand reiterate our commitment to helping them ensure success and a healthy ROI, saidRodrick Miller, CEO of InvestPR. Puerto Rico currently has over 100 FDA approved pharmaceutical and bioscience plants, and is the U.S.s largest pharmaceutical manufacturing region.

View post:
CytoImmune Therapeutics and Biosimilar Sciences US to Move Biotechnology Operations to Puerto Rico - JD Supra

The global biotechnology market estimated to grow at a CAGR of 10.5% during the forecast period from 2018 to 2025. The market for biotechnology was valued at USD 218,012.1 Mn in 2017 and is estimated to reach US$ 471,336.4 Mn by 2025.

Download Sample Copy of This Report @ https://www.theinsightpartners.com/sample/TIPHE100001316/

The global biotechnology market is segmented on the basis of technology and application and geography. On the basis of technology, the biotechnology market is segmented into DNA sequencing, fermentation, cell based assay, nanobiotechnology, chromatography, PCR technology, tissue engineering and regeneration and others. On the basis of application, the biotechnology market is segmented into industrial/bio processing, bioinformatics, food & agriculture, health, natural resource & environment and others.

The biotechnology market is aimed to describe, define and estimate the forecast for market size of the biotechnology till 2025. The report strategically analyzes macro and micro-markets to entail the major factors impacting the growth of the global biotechnology market. The market report for biotechnology is appropriate to cater the needs and demands of various stakeholders that include pharmaceutical, biotechnology and medical companies in the form of research services.

The major players operating in the biotechnology market include Thermo Fisher Scientific Inc., Merck KGaA, PerkinElmer, Inc., Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., Danaher, QIAGEN, BD, Bio-Rad Laboratories, Inc., Illumina, Inc. and among others. The global biotechnology market is highly competitive and driven by large number of novel product launches and approvals. For instance, in April 2017, Illumina, Inc. introduced BaseSpace Informatics Suite, used to accelerate genomic data analysis for sequence lab.

Research study is a highly acclaimed resource that investors, market contestants, and other people interested in this Biotechnology report can use to intensely position themselves in the global Biotechnology market. It mentions the recent developments structures, future growth plans, and other significant aspects of the business key participants that define their growth in the global Biotechnology market.

Biotechnology Market Important Factors:

Biotechnology Industry research report is a meticulous investigation of the current scenario of the Biotechnology global and regional market, which covers several industry dynamics. The Biotechnology market research report is a resource, which provides current as well as upcoming technical and financial details with market risk, growing demand and raw materials. The thorough analysis in this report enables investors, CEOs, regional traders, suppliers, top vendors to understand the market in a better way and based on that knowledge make well-informed decisions.

Place a Direct Order of this Report https://www.theinsightpartners.com/buy/TIPHE100001316/

Note: If you have any special requirements related to Biotechnology Market Report please let us know and we will offer you the report as you want.

About us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defence.

Contact us:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

Read this article:
Biotechnology Market 2021: Report Aims to Outline and Forecast, Organization Sizes, Top Vendors Overview, Growth Factors, Industry Opportunity and End...